在阿里健康榜单上，"万汉"磷酸奥司他韦胶囊销量超过5万单，占据销量榜首；"速福达"玛巴洛沙韦销量超2万单，排名第6；"万汉靓力"磷酸奥司他韦胶 囊销量超1万单，排名第7。 11月27日，中国疾病预防控制中心发布数据显示，在全国门急诊流感样病例中，流感阳性率接近45%，整体进入中流行水平，部分省份已达高流行水平。 监测数据显示，流行高峰一般出现在12月中下旬至1月初，之后将进入下降阶段。 据苏州市卫健委消息，苏州目前已进入流感流行期，流行毒株以甲型H3N2为主。 随着流感活动快速上升，感冒退热、清热解毒、止咳平喘以及鼻喷类药物销量暴涨。 叮当快药数据显示，奥司他韦和玛巴洛沙韦两种药品销量上涨明显，其中奥司他韦近7天销量上涨率达237%，玛巴洛沙韦销量上涨率达180%。 京东买药平台上，11月的解热镇痛类药品成交额环比10月增长超过13倍，速福达、可威成交额环比增长超20倍，感冒咳嗽相关用药成交额环比增长超过 70%。 美团买药相关数据显示，11月以来，甲乙流特效药订单量增长超1倍。其中，玛巴洛沙韦片较上月增长超110%，磷酸奥司他韦颗粒较上月增长超85%。 但需要注意的是 流感药物并非人人适用 玛巴洛沙韦目前只 ...

Group 1 - The core viewpoint of the article highlights the significant increase in sales of flu medications, particularly Oseltamivir and Baloxavir, amid rising flu activity across multiple regions in China [1] - Dongyangguang Pharmaceutical (06887) experienced a stock price increase of over 4%, reaching HKD 44.12, with a trading volume of HKD 11.73 million [1] - The sales growth rate for Oseltamivir over the past week was reported at 237%, while Baloxavir saw an increase of 180% [1] Group 2 - Dongyangguang Pharmaceutical is recognized as the "king of flu medications," with its Oseltamivir (brand name: Kewai) holding a significant market share in China, particularly in the pediatric segment [1] - The overall sales revenue for Dongyangguang Pharmaceutical is projected to reach CNY 1.301 billion in the first half of 2025 [1]

Core Viewpoint - Dongyangguang Pharmaceutical (600673) has seen a significant stock price increase of over 4%, attributed to rising flu activity across multiple regions in China, leading to increased sales of flu medications like Oseltamivir and Baloxavir [1] Company Summary - Dongyangguang Pharmaceutical's stock rose by 4.65%, reaching HKD 44.12, with a trading volume of HKD 11.7372 million [1] - The company is recognized as the "King of Flu Medications," with its Oseltamivir (brand name: Kewai) holding a dominant market share in China, particularly in the pediatric segment [1] - Projected sales for the first half of 2025 are expected to reach CNY 1.301 billion [1] Industry Summary - Recent data indicates a notable increase in the sales of flu medications, with Oseltamivir's sales growth rate reaching 237% over the past week, and Baloxavir's sales increasing by 180% [1] - There has been a general uptick in sales for cold, fever-reducing, detoxifying, cough-relieving, and nasal spray medications [1]